Free Trial

Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Cytosorbents logo with Medical background
Remove Ads

Analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a note issued to investors on Tuesday. The brokerage set a "hold" rating on the medical research company's stock.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Cytosorbents presently has an average rating of "Moderate Buy" and a consensus target price of $4.67.

Check Out Our Latest Stock Report on Cytosorbents

Cytosorbents Stock Performance

CTSO stock traded down $0.00 during midday trading on Tuesday, reaching $1.10. 17,054 shares of the company's stock traded hands, compared to its average volume of 145,136. The firm has a market capitalization of $60.09 million, a PE ratio of -3.04 and a beta of 0.78. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The company has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.05. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Remove Ads

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in shares of Cytosorbents during the 4th quarter worth $30,000. Northern Trust Corp increased its holdings in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the last quarter. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% in the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after buying an additional 118,387 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents during the 4th quarter worth about $99,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after purchasing an additional 8,400 shares during the period. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

(Get Free Report)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

See Also

Should You Invest $1,000 in Cytosorbents Right Now?

Before you consider Cytosorbents, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.

While Cytosorbents currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads